The company says third-party clinical testing found that participants taking its supplement lost an average of six pounds over two months
As drugmakers race to meet soaring demand for GLP-1 treatments, Evolv is taking a different approach.
The startup has launched Evolv GLP-1, an oral supplement made from a proprietary yeast strain, embracing an emerging category called biomimetics, biologically engineered molecules designed to mimic the body’s natural processes.
Like prescription GLP-1 drugs such as Ozempic and Wegovy, Evolv’s supplement is intended to support appetite control and metabolic health, but the company says its biomimetic approach avoids the high price tags commonly associated with prescription GLP-1 treatments.
“We’ve created a new version of our body’s own GLP-1 that can withstand digestion, be absorbed from a pill and promote the body’s natural signaling pathways responsible for appetite and metabolic function with no eligibility barriers,” Evolv co-founder and CEO Cory Henderson, PhD, said. “It’s a molecular breakthrough that can transform how we support metabolic health and opens the door to a whole new era of efficacious biologics.”
The company says third-party clinical testing found that participants taking Evolv GLP-1 experienced an average of six pounds of weight loss and a three-inch waist reduction over two months, while maintaining muscle mass when combined with a healthy diet and exercise. The same study also reported an average reduction of 600 daily calories consumed without restrictive dieting.
Evolv GLP-1 is sold in 30-capsule bottles, intended as a one-month supply. Evolv lists the retail price at $148, with a monthly subscription option available at $125.80. The supplement is also HSA/FSA eligible.
“This isn’t just another supplement,” Evolv co-founder and chief operating officer Becca McCarthy said. “We’re building a new category at the intersection of biology and accessibility to reimagine how people take control of their metabolism, appetite and longevity with solutions that deliver real results and work with the body—not against it.”
Evolv says its GLP-1 supplement is only the start and that its biomimetic platform is being developed for other applications, including hair health and restoration, another area that is on the rise.
While Evolv presents its new supplement as an alternative, its arrival also speaks to a broader shift across fitness and wellness. At the recent ATN Innovation Summit, industry leaders emphasized that GLP-1s are not a standalone solution but a tool that should be paired with accountability, exercise and nutrition to preserve lean muscle mass and support long-term health.
Companies like Evolt and Anytime Fitness, for instance, are investing in body composition tracking to ensure members taking weight-loss aids maintain muscle as they shed pounds. Evolv’s early clinical results align with those concerns, suggesting biomimetic supplements could find a foothold among consumers and fitness operators looking for an accessible option in a fast-growing $111 billion market.
